Multiple Sclerosis Market Size, Drug Analysis, Epidemiology, Disease Management, Pipeline Assessment, Unmet Needs and Forecast to 2030

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

Multiple Sclerosis Market Report Overview

Multiple sclerosis (MS) disease-modifying therapies (DMTs) market size across the 7MM was valued at $18.9 billion in 2020 and is expected to achieve a CAGR of more than 4% during 2020-2030.

Multiple Sclerosis Market Outlook, 2020-2030 ($ Billion)

Multiple Sclerosis Market Outlook, 2020-2030 ($ Billion)

To gain more information about the multiple sclerosis market forecast, download a free report sample

The multiple sclerosis market research report provides an analysis of the current and future market competition in the global MS therapeutics market. The report also offers an insightful review of the key industry drivers, restraints, and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.

Market Size (2020) $18.9 billion
CAGR (2020 – 2030) >4%
Key Therapy Class Non-Mab Injectable Therapies, Mab Injectable Therapies, and Oral Therapies
Key Countries The US, France, Germany, Italy, The UK, Spain, and Japan
Leading Players Biogen, Merck Serono (EMD Serono in the US), Teva, and Bayer HealthCare

Multiple Sclerosis Market Drivers

The launch of efficacious pipeline products with convenient oral formulations or less-frequent dosing and the continued uptake of oral DMTs, which typically have a higher annual cost of therapy (ACOT) and improved compliance rates are the key factors driving the market growth. In addition, an increase in the number of DMT options that target progressive MS subtypes will also support market growth.

Multiple Sclerosis Market Segmentation by Therapy Class

Some of the key therapy classes in the multiple sclerosis market in the 7 MM are non-mAb injectable therapies, mAb injectable therapies, and oral therapies. Oral therapies had the highest share of the market in 2020 and is expected to continue its dominance during the forecast period. This growth is believed to result from the launch of pipeline oral DMTs that will increase the diversity of oral therapies and bring novel MOAs into the market.

Multiple Sclerosis Market Analysis by Therapy Class, 2020 (%)

Multiple Sclerosis Market Analysis by Therapy Class, 2020 (%)

For more therapy class insights into the multiple sclerosis market, download a free report sample

Multiple Sclerosis Market Segmentation by Countries

Some of the key countries in the multiple sclerosis market in the 7 MM are the US, France, Germany, Italy, the UK, Spain, and Japan. The US had the highest share of the market in 2020.

Multiple Sclerosis Market Analysis by Countries, 2020 (%)

Multiple Sclerosis Market Analysis by Countries, 2020 (%)

For more countries’ insights into the multiple sclerosis market, download a free report sample

Multiple Sclerosis Market - Competitive Landscape

The leading players in the MS market are Biogen, Merck Serono (EMD Serono in the US), Teva, and Bayer HealthCare. Some of the successful product launches include Bayer’s Betaseron, Biogen’s Avonex, Teva’s Copaxone, and Merck’s Rebif.

Scope

  • Overview of MS, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and disease management.
  • Annualized MS therapeutics market revenue, cost of therapy per patient, and treatment usage patterns in ≥20 years old patient segments forecast from 2020 to 2030.
  • Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for MS therapy. The most promising candidates in Phase III and IIb development are profiled.
  • Analysis of the current and future market competition in the global MS therapeutics market. Insightful review of the key industry drivers, restraints, and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications for the MS therapeutics market.

Key Highlights

  • Report deliverables include a Word report and an Excel-based forecast model
  • Forecast includes the 7 major markets (7MM)
  • Forecast covers the period 2020-2030

Reasons to Buy

The report will enable you to:

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the global multiple sclerosis therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global multiple sclerosis therapeutics market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counterstrategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships

AB Science
Banner Life Sciences LLC
Bayer
Biogen GmbH
Bristol-Myers Squibb
Clene Nanomedicine Inc
Elan Pharmaceuticals
Genentech
Genzyme
Genmab GlaxoSmithKline AG
Immunic Inc
Janssen
Mapi Pharma Ltd
MediciNova Inc
Merck Serona Ltd
Novartis AG
Teva LLC
Roche
Sanofi
TG Therapeutics LLC

Table of Contents

1 Multiple Sclerosis: Executive Summary – Updated March 2023, based on events up to Feb 28, 2023

2 Introduction – Updated March 2023, based on events up to Feb 28, 2023

3 Disease Overview – Updated March 2023, based on events up to Feb 28, 2023

4 Epidemiology – Updated March 2023, based on events up to Feb 28, 2023

5 Disease Management – Updated March 2023, based on events up to Feb 28, 2023

6 Competitive Assessment – Updated March 2023, based on events up to Feb 28, 2023

7 Unmet Needs and Opportunity Assessment – Updated March 2023, based on events up to Feb 28, 2023

8 R&D Strategies – Updated March 2023, based on events up to Feb 28, 2023

9 Pipeline Assessment – Updated March 2023, based on events up to Feb 28, 2023

10 Pipeline Valuation Analysis – Updated March 2023, based on events up to Feb 28, 2023

11 Current and Future Players – Updated March 2023, based on events up to Feb 28, 2023

12 Market Outlook – Updated March 2023, based on events up to Feb 28, 2023

13 Appendix – Updated March 2023, based on events up to Feb 28, 2023

Table

Table 1: MS: Key Metrics in the 7MM

Table 2: Risk factors and comorbid conditions associated with MS

Table 3: Revised 2017 McDonald criteria for the diagnosis of MS

Table 4: Treatment guidelines for MS

Table 5: Top three disease-modifying therapies prescribed for MS, by market, 2018

Table 6: Leading disease-modifying drugs for the treatment of MS, 2023

Table 7: MS market – global drivers and barriers, 2020-30

Table 8: Key events impacting sales for MS in the US, 2020-30

Table 9: MS market – drivers and barriers in the US, 2020-30

Table 10: Key events impacting sales for MS in the 5EU, 2020-30

Table 11: MS market – drivers and barriers in the 5EU, 2020-30

Table 12: Key events impacting sales for MS in Japan, 2020-30

Table 13: MS market – drivers and barriers in Japan, 2020-30

Table 14: High-prescribing physicians (non-KOLs) surveyed, By country

Figures

Figure 1: Global sales forecast by country for MS in 2020 and 2030

Figure 2: Analysis of the company portfolio gap in multiple sclerosis during the forecast period

Figure 3: Competitive assessment of the injectable late-stage pipeline agents that GlobalData expects to be licensed for the treatment of MS during the forecast period

Figure 4: Competitive assessment of the oral late-stage pipeline agents that GlobalData expects to be licensed for the treatment of MS during the forecast period

Figure 5: Accrual of disability in the three subtypes of MS

Figure 6: 7MM, diagnosed incidence of MS (cases per 100,000 population), men and women, all ages, 2020

Figure 7: 7MM, diagnosed prevalence of MS (%), men and women, all ages, 2020

Figure 8: 7MM, sources used and not used to forecast the diagnosed incident cases of MS

Figure 9: 7MM, sources used and not used to forecast the diagnosed prevalent cases of MS

Figure 10: 7MM, sources used and not used to forecast the diagnosed prevalent cases of MS by type

Figure 11: 7MM, diagnosed incident cases of MS, N, both sexes, all ages, 2020

Figure 12: 7MM, age-specific diagnosed incident cases of MS, N, both sexes, all ages, 2020

Figure 13: 7MM, sex-specific diagnosed incident cases of MS, N, all ages, 2020

Figure 14: 7MM, diagnosed prevalent cases of MS, N, both sexes, all ages, 2020

Figure 15: 7MM, age-specific diagnosed prevalent cases of MS, N, both sexes, all ages, 2020

Figure 16: 7MM, sex-specific diagnosed prevalent cases of MS, N, all ages, 2020

Figure 17: 7MM, diagnosed prevalent cases of MS by type, N, both sexes, all ages, 2020

Figure 18: Expanded Disability Status Scale (EDSS)

Figure 19: Algorithm for the treatment of MS with disease-modifying therapy (DMT)

Figure 20: Unmet needs and opportunities in MS

Figure 21: Overview of the development pipeline in MS

Figure 22: Key late-stage trials for the promising pipeline agents that GlobalData expects to be licensed for MS treatment in the 7MM during the forecast period

Figure 23: Competitive assessment of the injectable pipeline drugs benchmarked against the SOC Ocrevus

Figure 24: Competitive assessment of the oral pipeline drugs benchmarked against the SOC Tecfidera

Figure 25: Analysis of the company portfolio gap in MS during the forecast period

Figure 26: Global (7MM) sales forecast by country for multiple sclerosis in 2020 and 2030

Figure 27: Global (7MM) sales forecast by therapy class for multiple sclerosis in 2020 and 2030

Figure 28: Sales forecast by class for MS in the US in 2020 and 2030

Figure 29: Sales forecast by class for MS in the 5EU in 2020 and 2030

Figure 30: Sales forecast by class for MS in Japan in 2020 and 2030

Frequently asked questions

Multiple Sclerosis Market Size, Drug Analysis, Epidemiology, Disease Management, Pipeline Assessment, Unmet Needs and Forecast to 2030 standard reports
Currency USD
$10,995

Can be used by individual purchaser only

$32,985

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Multiple Sclerosis Market Size, Drug Analysis, Epidemiology, Disease Management, Pipeline Assessment, Unmet Needs and Forecast to 2030 was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Multiple Sclerosis Market Size, Drug Analysis, Epidemiology, Disease Management, Pipeline Assessment, Unmet Needs and Forecast to 2030 in real time.

  • Access a live Multiple Sclerosis Market Size, Drug Analysis, Epidemiology, Disease Management, Pipeline Assessment, Unmet Needs and Forecast to 2030 dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.